BRIEF-Shire reports positive results in phase 1b study of skin swelling drug Lanadelumab
* No serious adverse events or discontinuations due to adverse events were observed at all doses studied
Jan 10 Intrexon Corp
* Ziopharm and Intrexon announce cooperative research and development agreement with the National Cancer Institute utilizing sleeping beauty system to generate T Cells targeting Neoantigens Source text for Eikon: Further company coverage:
BRASILIA, Feb 23 Brazilian miner Vale SA said on Thursday its board had approved that a dividend of 4.7 billion reais ($1.53 billion), or 0.91 reais per share, be paid to shareholders.
* Continues to view Russia as a very attractive market and expects to see further growth in coming quarters Source text for Eikon: Further company coverage: